Alterity Therapeutics (ATHE) Receivables - Other (2020 - 2021)
Alterity Therapeutics (ATHE) posted Receivables - Other of $1.6 million for Q4 2021, down 99.96% on a QoQ basis from $3.8 billion in Q4 2020, and down 99.96% year-over-year from $3.8 billion in Q4 2020.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Receivables - Other (2020 - 2021) Analysis & Trends
Alterity Therapeutics has reported Receivables - Other for 2 years, with the latest figure at $1.6 million in Q4 2021.
- On a quarterly basis, Receivables - Other fell 99.96% year-over-year to $1.6 million in Q4 2021; TTM through Dec 2021 was $1.6 million, a 99.96% decrease from a year earlier, with the FY2020 full-year figure at $8247.8, changed N/A from the prior year.
- Receivables - Other was $1.6 million for Q4 2021 at Alterity Therapeutics, down from $3.8 billion in the prior quarter.
- The five-year high for Receivables - Other was $3.8 billion in Q4 2020, with the low at $8247.8 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 1.55 Mn |
| Dec 31, 2020 | 3.83 Bn |
| Jun 30, 2020 | 8,247.81 |